Clinical trials: Immunity
Malignant Pleural Mesothelioma
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
This clinical trial will evaluate the safety and immune response of the sequential administration cancer vaccine CRS-207 (with or without cyclophosphamide) followed by standard of care chemotherapy (pemetrexed and cisplatin).
- Trial name
- NCT01675765
- Testing
- Immunotherapy plus chemotherapy, Immunotherapy with cyclophosphamide plus chemotherapy
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Aduro Biotech, Inc.
Meningococcal Disease
Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)
The purpose of this extension study is to evaluate the immunogenicity and safety of a booster dose of a MenABCWY vaccine, administered 24 months after completion of the primary vaccination series, in subjects who previously…
- Trial name
- NCT01992536
- Testing
- MenABCWY+OMV, MenABCWY+¼OMV
- Where
- 13 sites in United States, Poland
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pancreatic Cancer
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
The purpose of this study is to study the safety and clinical activity of nivolumab and ipilimumab in combination with either sequential administration of CY/GVAX pancreas vaccine followed by CRS-207 (Arm A) or with…
- Trial name
- NCT03190265
- Testing
- Cyclophosphamide, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Obesity
Effect of Obesity on Immune Response to Pneumovax 23
Pneumococcal infections are a leading cause of adult and childhood hospitalization and death. It has been shown that obese individuals are at higher risk for this bacterial infection.
- Trial name
- ROVE (NCT02471014)
- Testing
- Pneumovax 23, Blood tests, Questionnaires
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Florida
Botulism
Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®
This Phase 2, open-label, uncontrolled study designed to evaluate safety, tolerability, and immunogenicity of a single dose of rBV A/B in healthy participants previously immunized with pentavalent botulinum toxoid (or pentavalent…
- Trial name
- NCT06112834
- Testing
- rBV A/B
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- California Department of Public Health
Influenza
Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children
A total of 88 children between 2 and 9 years of age will be randomized to receive a two dose schedule of either licensed live attenuated trivalent seasonal influenza vaccine (LAIV) or licensed inactivated seasonal influenza…
- Trial name
- NCT01246999
- Testing
- Live attenuated Influenza vaccine, Trivalent Influenza Vaccine, TIV followed by LAIV
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.
- Conditions
- Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL), High-grade B-cell Lymphoma (HGBCL)
- Trial name
- NCT04745559
- Testing
- Pneumococcal conjugate vaccine (PCV13), CD19 targeted CAR T Cell Therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Hepatitis C
Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination
This study aims to identify the innate and adaptive immune response to zoster vaccination. Half of the participants will be individuals with chronic hepatitis C, while the other half with healthy volunteers.The innate immune…
- Trial name
- NCT02590068
- Testing
- Zoster vaccine live
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Tuberculosis, AIDS-related Complex
Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs
This study will evaluate the lung's immune response to mycobacterium tuberculosis (Mtb) infection and will modulate that response with interferon-gamma.
- Trial name
- NCT00201123
- Testing
- Aerosol Interferon-Gamma, Subcutaneous interferon-gamma
- Where
- 2 sites in United States, South Africa
- Volunteers
- 89 people
- Sponsor
- NYU Langone Health
Smoking Cessation
Analysis of Aldehyde Biomarkers of Exposure and Host Response
Analysis of aldeyde biomarkers of exposure and host response The purpose of this prospective, open-label, clinical trial is to establish the feasibility and validity of exhaled breath condensate (EBC) biomarkers for use in…
- Trial name
- NCT00482690
- Testing
- nicotine polacrilex, nicotine transdermal system, nicotine inhaler
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Nebraska
Healthy
A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
The purpose of this study is to compare the body's immune response when vaccines are given alone versus when vaccines are given along with the study drug called ixekizumab. The vaccines protect against pneumonia and tetanus.
- Trial name
- NCT02543918
- Testing
- Ixekizumab, Boostrix®, Pneumovax®23
- Where
- 3 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Prevention of COVID-19
Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
This is a randomised controlled, adaptive, multicentre Phase II protocol evaluating different booster strategies in individuals aged 75 years and older already vaccinated against SARS-CoV-2.
- Trial name
- EU-COVAT-1 (NCT05160766)
- Testing
- Comirnaty (BTN162b2), Spikevax (mRNA-1273)
- Where
- 9 sites in Germany, Lithuania and 2 more
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Oliver Cornely, MD
Meningococcal Disease
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
In this extension study, V59P20E1, the sponsor was planning to assess 5-year antibody persistence in subjects who received one or two doses of MenACWY conjugate vaccine at 2 to 10 years of age, and to evaluate response to a…
- Trial name
- NCT01823536
- Testing
- Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
- Where
- 16 sites in United States, Ukraine
- Volunteers
- 465 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Hepatitis B
Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder
The purpose of this study is to assess the long-term persistence of immunity to hepatitis B in adolescents aged 15-16 years who were vaccinated with Engerix™-B Kinder in infancy.
- Trial name
- NCT01847430
- Testing
- Engerix™-B Kinder
- Where
- 10 sites in Germany
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19 Vaccination
RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination
This is a randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of two polypore mushrooms, Fomitopsis officinalis and Trametes versicolor (FoTv), for use as an adjunct to vaccination for COVID-19 in a…
- Trial name
- MACH19 (NCT04951336)
- Testing
- FoTv
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
HIV Infections
Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection
The objective of the study is to compare two different doses of Peg-INF-α-2A (90 or 180 ug/wk) for their ability to maintain viral control when initiated 5 weeks before ART (antiretroviral therapy) interruption in HIV positive…
- Trial name
- NCT00594880
- Testing
- Pegylated Interferon-alpha 2a, 180 mcg/week sc, Pegylated Interferon-alpha 2a, 90 mcg/week sc
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- The Wistar Institute
HIV Infections
Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents
Complications with current HIV antiretroviral therapy have left many children and adolescents with limited therapeutic options due to drug resistance.
- Trial name
- NCT00766597
- Testing
- Vicriviroc
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 9 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mantle Cell Lymphoma, Lymphoma, Mantle Cell
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
This study will evaluate the safety and effectiveness of an experimental cancer vaccine for mantle cell lymphoma a form of cancer of the white blood cells called lymphocytes.
- Trial name
- NCT00005780
- Testing
- EPOCH-R, GM-CSF, Idiotype vaccine
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat certain hematologic malignancies not responding to standard treatment.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
- Trial name
- NCT00276159
- Testing
- 852A
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Poliomyelitis
A Study to Evaluate Pharyngeal Immunity to Poliovirus Type-2
The study will compare the poliovirus type-2 pharyngeal mucosal excretion in the first week, and at 2 and 4 weeks following the administration of a challenge novel OPV2 (nOPV2) dose at 18 weeks of age in 2 parallel groups of…
- Trial name
- NCT05677256
- Testing
- nOPV2
- Where
- Bangladesh
- Volunteers
- 501 people, healthy volunteers welcome
- Sponsor
- Fidec Corporation